NDASUBCUTANEOUSSOLUTION
Approved
Dec 2012
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
5/8 — Partial
SIGNIFOR (pasireotide) by Recordati is somatostatin receptor agonists [moa]. First approved in 2012.
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SIGNIFOR (pasireotide) is a somatostatin receptor agonist administered as a subcutaneous injection for treating neuroendocrine and pituitary disorders. It binds multiple somatostatin receptor subtypes to inhibit hormone secretion and tumor growth. The drug targets patients with acromegaly, Cushing's disease, and neuroendocrine tumors who require systemic hormone suppression.
$0.001BPart D
LOE ApproachingDeclining
3mo to LOELimited commercial momentum with declining claims and impending LOE; brand team is likely in defensive consolidation mode with minimal headcount expansion.
Mechanism of Action
Somatostatin Receptor Agonists
Pharmacologic Class:
Somatostatin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Study in Healthy Subjects to Investigate the Relative Bioavailability and Safety of Pasireotide After Single Subcutaneous Dose Administration Using a Reusable ServoPen With Cartridge as Compared to Administration Using a Syringe Drawn From an Ampule
Started Dec 2025
40 enrolled
PharmacokineticsSafety
Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor
Started Dec 2024
28 enrolled
Desmoplastic Small Round Cell TumorSynovial Sarcoma
A Study of Pasireotide in People With Prolactinoma
Started Feb 2024
10 enrolled
Prolactin-Producing Pituitary Tumor
Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia
Started Jan 2024
93 enrolled
Post-Bariatric Hypoglycemia
Pasireotide in Hyperinsulinemic Hypoglycemia
Started Apr 2017
0Congenital HyperinsulinismInsulinomaHyperinsulinism
Worked on SIGNIFOR at Recordati? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.